Which are the causes of Adult T-cell leukemia/lymphoma ATL?

Adult T-cell leukemia/lymphoma (ATL) is a rare and aggressive cancer of the T-lymphocytes caused by infection with the human T-lymphotropic virus type 1 (HTLV-1). While the virus is the primary cause, the development of Adult T-cell leukemia/lymphoma is a complex process that involves chronic viral infection, long-term immune system changes, and the accumulation of secondary genetic mutations over several decades.

What is the primary cause of Adult T-cell leukemia/lymphoma?

The fundamental cause of Adult T-cell leukemia/lymphoma is the HTLV-1 retrovirus. Unlike viruses that cause acute illnesses, HTLV-1 integrates its genetic material directly into the DNA of the host's T-cells. While millions of people worldwide carry HTLV-1, only about 3% to 5% of those infected will eventually develop Adult T-cell leukemia/lymphoma, typically after a latency period of 20 to 40 years.

What are the risk factors for developing ATL?

It is important to distinguish between the cause (the virus) and risk factors that increase the likelihood of the disease emerging. Transmission of HTLV-1, which leads to Adult T-cell leukemia/lymphoma, occurs primarily through:

• Mother-to-child transmission: Specifically through prolonged breastfeeding.


• Sexual contact: Unprotected sexual intercourse.


• Blood exposure: Sharing needles or receiving unscreened blood products.

What genetic and environmental factors contribute to ATL?

Beyond the initial infection, Adult T-cell leukemia/lymphoma progression is driven by genetic instability. The virus produces proteins like Tax and HBZ, which force infected cells to replicate uncontrollably while silencing genes that would normally stop tumor growth. Research indicates that the microenvironment—the surrounding immune cells—often fails to clear these infected cells, allowing Adult T-cell leukemia/lymphoma to manifest as a malignancy.

Is the cause of Adult T-cell leukemia/lymphoma fully understood?

While the role of HTLV-1 is well-established, researchers are still investigating why only a small fraction of carriers develop the malignancy. Current studies are focused on identifying specific biomarkers and epigenetic changes that predict who is at the highest risk, aiming to improve early detection and therapeutic interventions for Adult T-cell leukemia/lymphoma.

Next steps

• Consult an infectious disease specialist or hematologist-oncologist if you have tested positive for HTLV-1.


• Join the DiseaseMaps.org community to connect with others who are navigating the challenges of this rare condition.


• Discuss current clinical trials for targeted therapies with your medical team.

Medical disclaimer: This information is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Adult T-cell leukemia/lymphoma


• Orphanet: Adult T-cell leukemia/lymphoma


• OMIM (Online Mendelian Inheritance in Man): HTLV-1 infection and T-cell malignancy


• The Leukemia & Lymphoma Society (LLS): Information on T-cell malignancies